Improving cancer outcomes with Radioligand Therapies

POINT Biopharma is a clinical-stage global pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer. Radioligands offer improved efficacy and superior safety profiles versus platform chemotherapy agents and can provide patients and their families the very best possible outcomes.

Learn about POINT Biopharma

The Science of Radioligand Therapy

Although it may seem futuristic, radioligand therapy is a safe and proven treatment method for a variety of cancers.

First a scan is performed

Next the drug is administered

The drug then seeks out cancer

Learn about Radioligand Therapies

Our Treatment Pipeline

We are dedicated to expanding access to radiology therapies, making them applicable to more cancers, accessible to more people, and improving the lives of patients and their families. Here are the compounds we are currently developing:

Help improve the lives of patients and their families

We are hiring for clinical, manufacturing and business roles:

Careers at POINT Biopharma

News

POINT Biopharma and Isotopia Announce Lutetium-177 Clinical Supply Agreement

Isotopia to supply POINT with no-carrier-added Lu-177 for use in POINT’s Indianapolis, IN radioligand production facility

POINT Biopharma Debuts as Publicly Traded Next-Generation Radiotherapeutics Company

Common stock to commence trading on the Nasdaq Capital Market on July 1, 2021 under the ticker symbol “PNT”. Gross proceeds from the transaction totaled approximately $286.7 million.

POINT Biopharma Strengthens Senior Management Team with Appointment of Dr. Myra Rosario Herrle as EVP, Regulatory Affairs

POINT announced today the appointment of Myra Herrle, Ph.D., R.Ph., RAC as Executive Vice President of Regulatory Affairs. Dr. Herrle brings over 27 years of experience in the pharmaceutical industry in areas such as regulatory affairs ...